Mouse Anti-CD37 Recombinant Antibody (CBFYC-1243) (CBMAB-C1301-FY)

Okuno, S., Adachi, Y., Terakura, S., Julamanee, J., Sakai, T., Umemura, K., ... & Kiyoi, H. (2021). Spacer Length Modification Facilitates Discrimination between Normal and Neoplastic Cells and Provides Clinically Relevant CD37 CAR T Cells. The Journal of Immunology.

van der Horst, H. J., Oostindie, S. C., Cillessen, S. A., Gelderloos, A. T., Overdijk, M. B., Nijhof, I. S., ... & Mutis, T. (2021). Potent preclinical efficacy of DuoHexaBody-CD37 in B-cell malignancies. Hemasphere, 5(1).

Yan, X., Zhou, Q., Zhu, H., Liu, W., Xu, H., Yin, W., ... & Ren, C. (2021). The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas. Iscience, 24(11), 103249.

Oostindie, S. C., van der Horst, H. J., Kil, L. P., Strumane, K., Overdijk, M. B., van den Brink, E. N., ... & Breij, E. C. (2020). DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. Blood cancer journal, 10(3), 1-13.

Bobrowicz, M., Kubacz, M., Slusarczyk, A., & Winiarska, M. (2020). CD37 in B cell derived tumors—more than just a docking point for monoclonal antibodies. International Journal of Molecular Sciences, 21(24), 9531.

Zhang, Q., Han, Q., Zi, J., Song, C., & Ge, Z. (2020). CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia. Bioscience reports, 40(5), BSR20200008.

Malenge, M. M. (2020). Combination of anti-CD37 radioimmunotherapy with anti-CD20 immunotherapy and small molecule inhibitors to improve therapy of non-Hodgkin lymphoma.

Oostindie, S. C., Van Der Horst, H. J., Lindorfer, M. A., Cook, E. M., Tupitza, J. C., Zent, C. S., ... & Taylor, R. P. (2019). CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering. haematologica, 104(9), 1841.

Payandeh, Z., Noori, E., Khalesi, B., Mard-Soltani, M., Abdolalizadeh, J., & Khalili, S. (2018). Anti-CD37 targeted immunotherapy of B-Cell malignancies. Biotechnology letters, 40(11), 1459-1466.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols